跳至主要内容
临床试验/JPRN-jRCT2080223718
JPRN-jRCT2080223718已完成1 期

A Single-center, Open-label, Randomized, Two-treatment, Two-period Crossover Trial to Investigate Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

Otsuka Pharmaceutical Co., Ltd.0 个研究点目标入组 74 人开始时间: 2017年11月15日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
74

研究概览

简要总结

Bioequivalence for aripiprazole was confirmed between administration of ASC-01 and concomitant administration of aripiprazole and sertraline. There were no notable differences in safety or tolerability between administration of ASC-01 and concomitant administration of aripiprazole and sertraline. There were no notable differences in safety or tolerability between administration of ASC-01 under a fasting condition and under a fed condition.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 40age old(—)
性别
Male

入选标准

  • Subject has a body mass index (BMI = body weight [kg]/height [m]2) of larger than 18.5inclusive and smaller than 25.0 kg/m2 at screening.
  • - Subject is providing consent for participation in this trial in writing prior to the start of the procedures related to this trial, and judged by the investigator or subinvestigator to be capable of observing procedures in this trial.

排除标准

  • - Subject is judged by the investigator or subinvestigator to be inappropriate for participation in this trial.

研究者

相似试验